Shopping Cart
- Remove All
- Your shopping cart is currently empty
KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $4,250 | Backorder |
Description | KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities. |
In vitro | The compound, KRAS G12C inhibitor 18 (compound 34), effectively suppresses the proliferation of various tumor cell lines harboring the KRas G12C mutation, including H358, SW1436, and MiaPaca-2 cells, among others[1]. |
In vivo | KRAS G12C inhibitor 18 demonstrates a dose-dependent reduction in pERK and active KRas levels, evident at 8 hours post-administration, with single doses ranging from 12.5 to 100 mg/kg[1]. Additionally, at a dosage of 30 mg/kg administered orally twice daily, it exhibits significant anti-tumor activity in a lung cancer H358 xenograft mouse model[1]. |
Molecular Weight | 510.97 |
Formula | C25H20ClFN4O3S |
Cas No. | 2649788-45-2 |
Relative Density. | 1.52 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.